SciSparc (SPRC) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SciSparc is the larger company by market cap ($2.6 million vs $2.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPRC | XRTX |
|---|---|---|
| Share price | $4.47 | $1.41 |
| Market cap | $2.60M | $2.56M |
| 1-day change | +0.90% | -23.78% |
| P/E ratio (TTM) | 0.02 | — |
| Forward P/E | — | 1.76 |
| EPS (TTM) | $248.24 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.65 | $7.05 |
| 52-week low | $2.98 | $1.36 |
| Distance from 52-week high | -89.76% | -80.00% |
| Average volume | 179.62K | 376.30K |
| Shares outstanding | 580.97K | 1.82M |
| Employees | 3 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
SPRC vs XRTX FAQ
Which is bigger, SciSparc or XORTX Therapeutics?
SciSparc (SPRC) is larger, with a market capitalization of $2.60M compared with $2.56M for XORTX Therapeutics (XRTX).
Are SciSparc and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.